Watch this live webinar for perspectives on Alzheimer’s Disease biomarkers in Down syndrome from leading experts, Dr. André Strydom and Dr. Juan Fortea, with the Londowns Consortium and the Down Alzheimer Barcelona Neuroimaging Initiative.
May 31, 2018
Register at http://bit.ly/AlzBiomarkers4Ds
|Dr. André Strydom (MRCPsych, MSc, PhD)
King’s College LondonDr. Strydom is a Professor in Intellectual Disabilities at the world-leading Institute of Psychiatry, Psychology and Neuroscience at King’s College London, where his research is focused on mental disorders in adults with neurodevelopmental conditions, including Down syndrome and other genetic disorders.Professor Strydom is particularly interested in ageing-related conditions such as dementia in adults with Intellectual Disability and Down syndrome. He is the chief investigator of the LonDownS consortium http://www.ucl.ac.uk/london-down-syndrome-consortium which consists of several research groups from prominent London universities (KCL, UCL, QMUoL, Birkbeck and the Crick Institute) working on various aspects of Alzheimer’s disease in Down syndrome. One of the important aims of the consortium is to deliver the knowledge, tools and expertise that is necessary to enable clinical trials of treatment to prevent or delay the onset of dementia in individuals with Down syndrome.
|Dr. Juan Fortea, Faculty Neurologist.
Hospital de la Santa Creu I Sant Pau and Fundació Catalana Síndrome de Down.Dr. Fortea has extensive experience in clinical practice and in medical research, whose focus is the early diagnosis of neurodegenerative diseases, particularly Alzheimer’s disease as well as its development in Down syndrome.Dr. Fortea’s PhD specialization was the study of pre-‐clinical Alzheimer disease in sporadic and familial cohorts through the use of multimodal MRI and CSF studies. Today, he is the principal investigator of multiple research projects in the field of Alzheimer’s disease and Down syndrome, and he leads the Neuroimaging Laboratory within the St Pau Memory Unit. One of his most significant contributions is the creation and implementation of a health plan for the screening of Alzheimer’s disease in adults with Down syndrome that includes longitudinal assessments and a comprehensive biomarker research program. This cohort is one of the largest in the world complete with multimodal biomarkers, including MRI and PET imaging, plasma and CSF as well as polysomnography tests.